Trial Profile

Phase I, Randomized, Open-Label, Single-Dose, Three Period, Six-Sequence Crossover Study to Determine the Relative Bioavailability of the Evobrutinib Intended Commercial Tablet Formulation (TF2) Compared to the Clinical Tablet Formulation (TF1) and Evaluate the Effect of Food on TF2 Bioavailability in Healthy Participants

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 13 Jul 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Evobrutinib (Primary)
Indications Autoimmune disorders; Encephalomyelitis; Multiple sclerosis; Rheumatoid arthritis; Systemic lupus erythematosus
Focus Pharmacokinetics
Sponsors Merck KGaA

08 Jul 2020 Status changed from recruiting to completed.
08 Jun 2020 Planned End Date changed from 8 Apr 2020 to 21 Jun 2020.
08 Jun 2020 Planned primary completion date changed from 8 Apr 2020 to 21 Jun 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com